The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide

Leukemia and Lymphoma

Volumn 55, Issue 2, 2014, Pages 337-341

  Wang, Tzu Fei ^a   Ahluwalia, Rohan ^a   Fiala, Mark A ^a   Trinkaus, Kathryn M ^a   Cox, Doug P ^a   Jaenicke, Matthew ^a   Moliske, Caitlin C ^a   Carson, Kenneth R ^a   Wildes, Tanya M ^a   Tomasson, Michael H ^a   Stockerl Goldstein, Keith E ^a   Vlj, Ravi ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bortezomib; Carfilzomib; Lenalidomide; Multiple myeloma; Pomalidomide

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; BORTEZOMIB; CARFILZOMIB; LENALIDOMIDE; POMALIDOMIDE; THALIDOMIDE;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DRUG RESISTANCE, NEOPLASM; DRUG TOLERANCE; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PYRAZINES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; THALIDOMIDE;

EID: 84904306092     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.803547     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Kumar SK, Rajkumar SV, Dispenzieri A, et al Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008;111:2516-2520.
3. Kumar SK, Lee JH, Lahuerta J.J., et al Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149-157.
4. FDA. Carfilzomib. 2012. Available from: http://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs/ucm312945.htm
5. FDA. FDA approves Pomalyst for advanced multiple myeloma. 2013. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm338895.htm
6. Siegel DS, Martin T, Wang M., et al A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817-2825.
7. Vij R, Siegel DS, Jagannath S, et al An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158:739-748.
8. Lacy MQ, Alfred JB, Gertz M.A., et al Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood 2011;118:2970-2975.
9. Leleu X, Attal M, Arnulf B., et al Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. Blood 2013;121:1968-1975.
10. Durie BG, Harousseau IL, Miguel J.S., et al International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473. (Pubitemid 44264086)
11. Dimopoulos M, Spencer A, Attal M., et al Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132. (Pubitemid 350146107)
12. Weber DM, Chen C, Niesvlzky R., et al Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142. (Pubitemid 350146108)
13. Wang M, Dimopoulos MA, Chen C, et al Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112:4445-4451.
14. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007;109:3489-3495. (Pubitemid 46572539)
15. Larson D, Kyle RA, Rajkumar SV Prevalence and monitoring of oligosecretory myeloma. N Engl J Med 2012;367:580-581.
16. Short KD, Rajkumar SV, Larson D, et al Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia 2011;25:906-908.
17. Dimopoulos MA, Lacy MQ, Moreau P, et al Pomalidomide in combination with low-dose dexamethasone: Demonstrates a significant progression free survival and overall survival advantage, in relapsed/ refractory MM:A phase 3, multicenter, randomized, open-label study. Blood 2012;120(Suppl. 1): Abstract LBA-6.
18. Richardson PG, Weller E, Lonial S., et al Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-686.
19. Anderson KC, Jagannath S, Jakubowiak A.J., et al Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): encouraging outcomes and tolerability in a phase II study. J Clin Oncol 2009;27(Suppl.): Abstract 8536.
20. Vij R, Richardson PG, Jagannath S, et al Pomalidomide with or without low-dose dexamethasone in patients with relapsed/refractory multiple myeloma: outcomes in patients refractory to lenalidomide and bortezomib. J Clin Oncol 2012;30(Suppl.): Abstract 8016.